Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety ...

Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved ...

Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...

The introduction of biosimilars in the treatment of age-related macular degeneration (AMD) is raising concerns among ...

Sarfaraz Niazi, PhD, urges the FDA to let the USPharmacopeia (USP) create product release specifications for biosimilars to ...

Although more research is needed in pediatric patients, biosimilars could improve treatment access and reduce costs.

Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 ...

Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 ...

Number 5: A prospective cohort study found that switching back from the biosimilar SB2 to the reference infliximab did not affect clinical disease activity or safety in inflammatory bowel disease (IBD ...

The denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and ...